Immuron Limited is an Australian biopharmaceutical company specializing in the development and commercialization of orally delivered targeted polyclonal antibodies, with a primary focus on treating infectious and inflammatory diseases of the gastrointestinal tract. Founded in 1994 and headquartered in Blackburn North, Immuron operates as both a commercial enterprise and a clinical-stage innovator, leveraging patented technology that utilizes polyclonal immunoglobulins derived from hyper-immune bovine colostrum. These orally administered antibodies are designed to act within the digestive system, providing targeted intervention for enteric conditions without systemic absorption. The company’s notable product portfolio includes Travelan, aimed at reducing the risk of travellers’ diarrhoea, and Protectyn, which supports gut and liver function; both reflect Immuron’s emphasis on addressing unmet medical needs in gastrointestinal and immune health. Immuron also advances clinical candidates for conditions such as Clostridioides difficile infections and Enterotoxigenic Escherichia coli (ETEC). Operating in the health technology and biotechnology sector, Immuron Limited is a key participant in Australia’s healthcare innovation landscape, serving pharmacy, online, and practitioner networks across Australia, the US, and Canada. Its research and product development contribute to advancements in passive immunotherapy and digestive health solutions.